Peptidream Inc. (4587) Press Release
Consolidated Financial Results for the Six Months Ended June 30, 2026 [IFRS]
Earlier from Peptidream
- Initiation of Phase 1 Clinical Trial by Novartis Marks Milestone for PeptiDream
- PeptiDream Strengthens Leadership Team with Multiple Key Executive Appointments
- PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
- PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan